α-Synuclein: A therapeutic target for Parkinson's disease?

Pharmacological Research

Volumn 58, Issue 5-6, 2008, Pages 271-280

  Maguire Zeiss, Kathleen A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Synuclein; Oligomers; Parkinson's disease; Protein misfolding; Therapeutics

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE A2A RECEPTOR ANTAGONIST; ALPHA SYNUCLEIN; ANTIOXIDANT; ANTIPARKINSON AGENT; BROMOCRIPTINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HERBICIDE; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUSTRIAL CHEMICAL; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROPROTECTIVE AGENT; NEUROTOXIN; PESTICIDE; PRION PROTEIN; SELEGILINE; SIRTUIN; UBIDECARENONE; UNINDEXED DRUG; VIRUS VECTOR;

BRAIN DEPTH STIMULATION; CHOLESTEROL METABOLISM; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE PREDISPOSITION; DOPAMINERGIC SYSTEM; DRUG TARGETING; DRUG WITHDRAWAL; DYSKINESIA; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; GENE THERAPY; HUMAN; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; VIRAL GENE DELIVERY SYSTEM;

ALPHA-SYNUCLEIN; ANIMALS; ANTIPARKINSON AGENTS; HUMANS; PARKINSON DISEASE;

EID: 56649118950     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.09.006     Document Type: Review

References (257)

1. Parkinson J. An essay on the shaking palsy (1817), Sherwood, Neely, and Jones, Paternoster Row, London
2. Braak H., and Del Tredici K. Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 70 (2008) 1916-1925
3. Jellinger K.A. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 116 (2008) 1-16
4. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95 (1998) 6469-6473
5. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
6. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for hla-dr in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
7. Knott C., Stern G., and Wilkin G.P. Inflammatory regulators in Parkinson's disease: inos, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 16 (2000) 724-739
8. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 57 (2005) 168-175
9. Carlsson A., Lindqvist M., and Magnusson T. 3,4-dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180 (1957) 1200
10. Abbott A. Neuroscience: the molecular wake-up call. Nature 447 (2007) 368-370
11. Ehringer H., and Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 38 (1960) 1236-1239
12. Birkmayer W., and Hornykiewicz O. The l-3,4-dioxyphenylalanine (dopa)-effect in Parkinson-akinesia. Wien Klin Wochenschr 73 (1961) 787-788
13. Birkmayer W., and Hornykiewicz O. The effect of l-3,4-dihydroxyphenylalanine (dopa) on akinesia in parkinsonism. English Translation. 1961. Wien Klin Wochenschr 113 (2001) 851-854
14. Klein C., and Schlossmacher M.G. Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology 69 (2007) 2093-2104
15. Maguire-Zeiss K.A., and Federoff H.J. Convergent pathobiologic model of Parkinson's disease. Ann N Y Acad Sci 991 (2003) 152-166
16. Schiesling C., Kieper N., Seidel K., and Kruger R. Review: familial Parkinson's disease-genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathol Appl Neurobiol 34 (2008) 255-271
17. Abbas N., Lucking C.B., Ricard S., Durr A., Bonifati V., De Michele G., et al. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's disease genetics study group and the European consortium on genetic susceptibility in Parkinson's disease. Hum Mol Genet 8 (1999) 567-574
18. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
19. Lucking C.B., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's disease genetics study group. N Engl J Med 342 (2000) 1560-1567
20. Benbunan B.R., Korczyn A.D., and Giladi N. Parkin mutation associated parkinsonism and cognitive decline, comparison to early onset Parkinson's disease. J Neural Transm 111 (2004) 47-57
21. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., et al. Hereditary early-onset Parkinson's disease caused by mutations in pink1. Science 304 (2004) 1158-1160
22. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., et al. Mutations in the dj-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
23. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., et al. Mutations in lrrk2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607
24. Facheris M., Strain K.J., Lesnick T.G., de Andrade M., Bower J.H., Ahlskog J.E., et al. Uchl1 is associated with Parkinson's disease: a case-unaffected sibling and case-unrelated control study. Neurosci Lett 381 (2005) 131-134
25. Maraganore D.M., Lesnick T.G., Elbaz A., Chartier-Harlin M.C., Gasser T., Kruger R., et al. UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol 55 (2004) 512-521
26. Toda T., Momose Y., Murata M., Tamiya G., Yamamoto M., Hattori N., et al. Toward identification of susceptibility genes for sporadic Parkinson's disease. J Neurol 250 Suppl. 3 (2003) III40-III43
27. Cho J.W., Kim S.Y., Park S.S., Kim H.J., Ahn T.B., Kim J.M., et al. The g2019s lrrk2 mutation is rare in Korean patients with Parkinson's disease. Can J Neurol Sci 34 (2007) 53-55
28. Wintermeyer P., Kruger R., Kuhn W., Muller T., Woitalla D., Berg D., et al. Mutation analysis and association studies of the uchl1 gene in German Parkinson's disease patients. Neuroreport 11 (2000) 2079-2082
29. Wood-Kaczmar A., Gandhi S., and Wood N.W. Understanding the molecular causes of Parkinson's disease. Trends Mol Med 12 (2006) 521-528
30. Polymeropoulos M.H. Genetics of Parkinson's disease. Ann N Y Acad Sci 920 (2000) 28-32
31. Polymeropoulos M.H., Higgins J.J., Golbe L.I., Johnson W.G., Ide S.E., Di Iorio G., et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274 (1996) 1197-1199
32. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
33. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., et al. Ala30pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18 (1998) 106-108
34. Singleton A., Gwinn-Hardy K., Sharabi Y., Li S.T., Holmes C., Dendi R., et al. Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain 127 (2004) 768-772
35. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
36. Ahn T.B., Kim S.Y., Kim J.Y., Park S.S., Lee D.S., Min H.J., et al. Alpha-synuclein gene duplication is present in sporadic Parkinson disease. Neurology 70 (2008) 43-49
37. Maroteaux L., Campanelli J.T., and Scheller R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8 (1988) 2804-2815
38. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 90 (1993) 11282-11286
39. Chandra S., Chen X., Rizo J., Jahn R., and Sudhof T.C. A broken alpha-helix in folded alpha-synuclein. J Biol Chem 278 (2003) 15313-15318
40. Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., and Ferrante R.J. Mptp induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11 (2000) 211-213
41. Paxinou E., Chen Q., Weisse M., Giasson B.I., Norris E.H., Rueter S.M., et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci 21 (2001) 8053-8061
42. Souza J.M., Giasson B.I., Chen Q., Lee V.M., and Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 275 (2000) 18344-18349
43. Uversky V.N., Lee H.J., Li J., Fink A.L., and Lee S.J. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem 276 (2001) 43495-43498
44. Uversky V.N., Li J., and Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular link between Parkinson's disease and heavy metal exposure. J Biol Chem 276 (2001) 44284-44296
45. Uversky V.N., Li J., and Fink A.L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 276 (2001) 10737-10744
46. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., and Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 277 (2002) 1641-1644
47. Li J., Zhu M., Manning-Bog A.B., Di Monte D.A., and Fink A.L. Dopamine and l-dopa disaggregate amyloid fibrils: Implications for Parkinson's and Alzheimer's disease. FASEB J 18 (2004) 962-964
48. Rochet J.C., Outeiro T.F., Conway K.A., Ding T.T., Volles M.J., Lashuel H.A., et al. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci 23 (2004) 23-34
49. Fink A.L. The aggregation and fibrillation of alpha-synuclein. Acc Chem Res 39 (2006) 628-634
50. Cappai R., Leck S.L., Tew D.J., Williamson N.A., Smith D.P., Galatis D., et al. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J 19 (2005) 1377-1379
51. Maguire-Zeiss K.A., Wang C.I., Yehling E., Sullivan M.A., Short D.W., Su X., et al. Identification of human alpha-synuclein specific single chain antibodies. Biochem Biophys Res Commun 349 (2006) 1198-1205
52. Moussa C.E., Mahmoodian F., Tomita Y., and Sidhu A. Dopamine differentially induces aggregation of a53t mutant and wild type alpha-synuclein: Insights into the protein chemistry of Parkinson's disease. Biochem Biophys Res Commun 365 (2008) 833-839
53. George J.M., Jin H., Woods W.S., and Clayton D.F. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15 (1995) 361-372
54. Bonini N.M., and Giasson B.I. Snaring the function of alpha-synuclein. Cell 123 (2005) 359-361
55. Chandra S., Gallardo G., Fernandez-Chacon R., Schluter O.M., and Sudhof T.C. Alpha-synuclein cooperates with cspalpha in preventing neurodegeneration. Cell 123 (2005) 383-396
56. Sidhu A., Wersinger C., and Vernier P. Alpha-synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett 565 (2004) 1-5
57. Sidhu A., Wersinger C., and Vernier P. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?. FASEB J 18 (2004) 637-647
58. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 (2000) 239-252
59. Barcelo-Coblijn G., Golovko M.Y., Weinhofer I., Berger J., and Murphy E.J. Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice. J Neurochem 101 (2007) 132-141
60. Golovko M.Y., Faergeman N.J., Cole N.B., Castagnet P.I., Nussbaum R.L., and Murphy E.J. Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of alpha-synuclein palmitate binding. Biochemistry 44 (2005) 8251-8259
61. Golovko M.Y., Rosenberger T.A., Faergeman N.J., Feddersen S., Cole N.B., Pribill I., et al. Acyl-coa synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolism. Biochemistry 45 (2006) 6956-6966
62. Golovko M.Y., Rosenberger T.A., Feddersen S., Faergeman N.J., and Murphy E.J. Alpha-synuclein gene ablation increases docosahexaenoic acid incorporation and turnover in brain phospholipids. J Neurochem 101 (2007) 201-211
63. Perez R.G., and Hastings T.G. Could a loss of alpha-synuclein function put dopaminergic neurons at risk?. J Neurochem 89 (2004) 1318-1324
64. Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., and Zigmond M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22 (2002) 3090-3099
65. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., et al. Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40 (2001) 7812-7819
66. Danzer K.M., Haasen D., Karow A.R., Moussaud S., Habeck M., Giese A., et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27 (2007) 9220-9232
67. Chesselet M.F. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?. Exp Neurol 209 (2008) 22-27
68. Emborg M.E. Nonhuman primate models of Parkinson's disease. Ilar J 48 (2007) 339-355
69. Kahle P.J. Alpha-synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol 115 (2008) 87-95
70. Meredith G.E., Sonsalla P.K., and Chesselet M.F. Animal models of Parkinson's disease progression. Acta Neuropathol 115 (2008) 385-398
71. Terzioglu M., and Galter D. Parkinson's disease: genetic versus toxin-induced rodent models. FEBS J 275 (2008) 1384-1391
72. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 (2000) 1301-1306
73. Conway K.A., Harper J.D., and Lansbury Jr. P.T. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39 (2000) 2552-2563
74. Feany M.B., and Bender W.W. A Drosophila model of Parkinson's disease. Nature 404 (2000) 394-398
75. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 (2001) 1346-1349
76. Gomez-Santos C., Ferrer I., Reiriz J., Vinals F., Barrachina M., and Ambrosio S. Mpp+ increases alpha-synuclein expression and erk/map-kinase phosphorylation in human neuroblastoma sh-sy5y cells. Brain Res 935 (2002) 32-39
77. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., et al. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10 (1999) 717-721
78. Lee M., Hyun D., Halliwell B., and Jenner P. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 76 (2001) 998-1009
79. Tabrizi S.J., Orth M., Wilkinson J.M., Taanman J.W., Warner T.T., Cooper J.M., et al. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 9 (2000) 2683-2689
80. Takenouchi T., Hashimoto M., Hsu L.J., Mackowski B., Rockenstein E., Mallory M., et al. Reduced neuritic outgrowth and cell adhesion in neuronal cells transfected with human alpha-synuclein. Mol Cell Neurosci 17 (2001) 141-150
81. Beal M.F. Experimental models of Parkinson's disease. Nat Rev Neurosci 2 (2001) 325-334
82. Betarbet R., Sherer T.B., and Greenamyre J.T. Animal models of Parkinson's disease. Bioessays 24 (2002) 308-318
83. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287 (2000) 1265-1269
84. Richfield E.K., Thiruchelvam M.J., Cory-Slechta D.A., Wuertzer C., Gainetdinov R.R., Caron M.G., et al. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol 175 (2002) 35-48
85. van der Putten H., Wiederhold K.H., Probst A., Barbieri S., Mistl C., Danner S., et al. Neuropathology in mice expressing human alpha-synuclein. J Neurosci 20 (2000) 6021-6029
86. Yang F., Ueda K., Chen P., Ashe K.H., and Cole G.M. Plaque-associated alpha-synuclein (nacp) pathology in aged transgenic mice expressing amyloid precursor protein. Brain Res 853 (2000) 381-383
87. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D., et al. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 274 (1999) 9843-9846
88. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., and Wolozin B. The a53t alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20 (2000) 6048-6054
89. Giasson B.I., and Lee V.M. A new link between pesticides and Parkinson's disease. Nat Neurosci 3 (2000) 1227-1228
90. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., et al. Parkinson-like syndrome induced by continuous mptp infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA 102 (2005) 3413-3418
91. Recchia A., Rota D., Debetto P., Peroni D., Guidolin D., Negro A., et al. Generation of a alpha-synuclein-based rat model of Parkinson's disease. Neurobiol Dis 30 (2008) 8-18
92. Su X., Maguire-Zeiss K.A., Giuliano R., Prifti L., Venkatesh K., and Federoff H.J. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging 29 (2008) 1690-1701
93. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19 (2005) 533-542
94. Reynolds A.D., Kadiu I., Garg S.K., Glanzer J.G., Nordgren T., Ciborowski P., et al. Nitrated alpha-synuclein and microglial neuroregulatory activities. J Neuroimmune Pharmacol 3 (2008) 59-74
95. McGeer P.L., and McGeer E.G. Glial reactions in Parkinson's disease. Mov Disord 23 (2008) 474-483
96. Mizuno Y., Shimoda-Matsubayashi S., Matsumine H., Morikawa N., Hattori N., and Kondo T. Genetic and environmental factors in the pathogenesis of Parkinson's disease. Adv Neurol 80 (1999) 171-179
97. Riess O., and Kruger R. Parkinson's disease-a multifactorial neurodegenerative disorder. J Neural Transm Suppl. 56 (1999) 113-125
98. Seidler A., Hellenbrand W., Robra B.P., Vieregge P., Nischan P., Joerg J., et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology 46 (1996) 1275-1284
99. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., Cory-Slechta D.A., et al. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 10 (2002) 119-127
100. Maguire-Zeiss K.A., Short D.W., and Federoff H.J. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?. Brain Res Mol 134 (2005) 18-23
101. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Kortsha G.X., Brown G.G., et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 20 (1999) 239-247
102. Coon S., Stark A., Peterson E., Gloi A., Kortsha G., Pounds J., et al. Whole-body lifetime occupational lead exposure and risk of Parkinson's disease. Environ Health Perspect 114 (2006) 1872-1876
103. Kamel F., Tanner C., Umbach D., Hoppin J., Alavanja M., Blair A., et al. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am J Epidemiol 165 (2007) 364-374
104. Priyadarshi A., Khuder S.A., Schaub E.A., and Priyadarshi S.S. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res 86 (2001) 122-127
105. Barlow B.K., Cory-Slechta D.A., Richfield E.K., and Thiruchelvam M. The gestational environment and Parkinson's disease: evidence for neurodevelopmental origins of a neurodegenerative disorder. Reprod Toxicol 23 (2007) 457-470
106. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., and Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and pet imaging. Eur J Neurosci 15 (2002) 991-998
107. Delgado M., and Ganea D. Neuroprotective effect of vasoactive intestinal peptide (vip) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J 17 (2003) 944-946
108. Gao H.M., Liu B., Zhang W., and Hong J.S. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J 17 (2003) 1957-1959
109. Wu D.C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 100 (2003) 6145-6150
110. Barcia C., Sanchez Bahillo A., Fernandez-Villalba E., Bautista V., Poza Y.P.M., Fernandez-Barreiro A., et al. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 46 (2004) 402-409
111. Saint-Pierre M., Tremblay M.E., Sik A., Gross R.E., and Cicchetti F. Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats. J Neurochem 98 (2006) 760-772
112. Gash D.M., Rutland K., Hudson N.L., Sullivan P.G., Bing G., Cass W.A., et al. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol 63 (2008) 184-192
113. Sugeno N., Takeda A., Hasegawa T., Kobayashi M., Kikuchi A., Mori F., et al. Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death. J Biol Chem 283 (2008) 23179-23188
114. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
115. Langston J.W., Irwin I., Langston E.B., and Forno L.S. 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 48 (1984) 87-92
116. Langston J.W., Langston E.B., and Irwin I. MPTP-induced Parkinsonism in human and non-human primates-clinical and experimental aspects. Acta Neurol Scand Suppl 100 (1984) 49-54
117. Ali S.F., David S.N., and Newport G.D. Age-related susceptibility to MPTP-induced neurotoxicity in mice. Neurotoxicology 14 (1993) 29-34
118. Chiba K., Trevor A.J., and Castagnoli Jr. N. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun 128 (1985) 1228-1232
119. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., and Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46 (1999) 598-605
120. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76 (2001) 1265-1274
121. Moratalla R., Quinn B., DeLanney L.E., Irwin I., Langston J.W., and Graybiel A.M. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 89 (1992) 3859-3863
122. Varastet M., Riche D., Maziere M., and Hantraye P. Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Neuroscience 63 (1994) 47-56
123. Hoppel C.L., Grinblatt D., Kwok H.C., Arora P.K., Singh M.P., Sayre L.M., et al. Inhibition of mitochondrial respiration by analogs of 4-phenylpyridine and 1-methyl-4-phenylpyridinium cation (mpp+), the neurotoxic metabolite of MPTP. Biochem Biophys Res Commun 148 (1987) 684-693
124. Mochizuki H., Nakamura N., Nishi K., and Mizuno Y. Apoptosis is induced by 1-methyl-4-phenylpyridinium ion (MPP+) in ventral mesencephalic-striatal co-culture in rat. Neurosci Lett 170 (1994) 191-194
125. Ramsay R.R., Dadgar J., Trevor A., and Singer T.P. Energy-driven uptake of n-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of mptp. Life Sci 39 (1986) 581-588
126. Ramsay R.R., Salach J.I., and Singer T.P. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem Biophys Res Commun 134 (1986) 743-748
127. Song D.D., Shults C.W., Sisk A., Rockenstein E., and Masliah E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with mptp. Exp Neurol 186 (2004) 158-172
128. Tatton N.A., and Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77 (1997) 1037-1048
129. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., and Marsden C.D. Mitochondrial complex i deficiency in Parkinson's disease. J Neurochem 54 (1990) 823-827
130. Gao H.M., Liu B., Zhang W., and Hong J.S. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro mptp model of Parkinson's disease. FASEB J 17 (2003) 1954-1956
131. Dong Z., Ferger B., Feldon J., and Bueler H. Overexpression of Parkinson's disease-associated alpha-synucleina53t by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to mptp. J Neurobiol 53 (2002) 1-10
132. Przedborski S., Chen Q., Vila M., Giasson B.I., Djaldatti R., Vukosavic S., et al. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp) mouse model of Parkinson's disease. J Neurochem 76 (2001) 637-640
133. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., and Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 74 (2000) 721-729
134. Meredith G.E., Totterdell S., Petroske E., Santa Cruz K., Callison Jr. R.C., and Lau Y.S. Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res 956 (2002) 156-165
135. Periquet M., Fulga T., Myllykangas L., Schlossmacher M.G., and Feany M.B. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 27 (2007) 3338-3346
136. Mori F., Nishie M., Kakita A., Yoshimoto M., Takahashi H., and Wakabayashi K. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra. J Neuropathol Exp Neurol 65 (2006) 808-815
137. Galvin J.E. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol 112 (2006) 115-126
138. Caudle W.M., Colebrooke R.E., Emson P.C., and Miller G.W. Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci 31 (2008) 303-308
139. Lee F.J., Liu F., Pristupa Z.B., and Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 15 (2001) 916-926
140. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 991 (2003) 1-14
141. Maguire-Zeiss K.A., and Federoff H.J. Novel gene therapeutic strategies for neurodegenerative diseases. Ernst Schering Res Found Workshop (2005) 147-171
142. Maguire-Zeiss K.A., Mhyre T.R., and Federoff H.J. Gazing into the future: Parkinson's disease gene therapeutics to modify natural history. Exp Neurol 209 (2008) 101-113
143. Benabid A.L. Deep brain stimulation for Parkinson's disease. Curr Opin Neurobiol 13 (2003) 696-706
144. Hsich G., Sena-Esteves M., and Breakefield X.O. Critical issues in gene therapy for neurologic disease. Hum Gene Ther 13 (2002) 579-604
145. Mochizuki H., and Mizuno Y. Gene therapy for Parkinson's disease. J Neural Transm Suppl (2003) 205-213
146. Schapira A.H., and Olanow C.W. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann Neurol 53 Suppl. 3 (2003) S149-S157 discussion S157-149
147. Klegeris A., McGeer E.G., and McGeer P.L. Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol 20 (2007) 351-357
148. Gao H.M., Liu B., Zhang W., and Hong J.S. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 24 (2003) 395-401
149. Shoulson I. Datatop: a decade of neuroprotective inquiry. Parkinson study group. Deprenyl and tocopherol antioxidative therapy of parkinsonism. Ann Neurol 44 (1998) S160-S166
150. Morizane A., Li J.Y., and Brundin P. From bench to bed: the potential of stem cells for the treatment of Parkinson's disease. Cell Tissue Res 331 (2008) 323-336
151. Wu S.S., and Frucht S.J. Treatment of Parkinson's disease: what's on the horizon?. CNS Drugs 19 (2005) 723-743
152. Takahashi J. Stem cell therapy for Parkinson's disease. Ernst Schering Res Found Workshop (2006) 229-244
153. Peterson A.L., and Nutt J.G. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 5 (2008) 270-280
154. Mochizuki H., Yasuda T., and Mouradian M.M. Advances in gene therapy for movement disorders. Neurotherapeutics 5 (2008) 260-269
155. Wang X., Liang X.B., Li F.Q., Zhou H.F., Liu X.Y., Wang J.J., et al. Therapeutic strategies for Parkinson's disease: the ancient meets the future-traditional Chinese herbal medicine, electroacupuncture, gene therapy and stem cells. Neurochem Res 33 (2008) 1956-1963
156. Palfi S. Towards gene therapy for Parkinson's disease. Lancet Neurol 7 (2008) 375-376
157. Fiske B.K., Frasier M.A., and Sherer T.B. Special focus section: gene therapy for Parkinson's disease. Exp Neurol 209 (2008) 28-29
158. Fiandaca M., Forsayeth J., and Bankiewicz K. Current status of gene therapy trials for Parkinson's disease. Exp Neurol 209 (2008) 51-57
159. Prasad K.N., Cole W.C., and Kumar B. Multiple antioxidants in the prevention and treatment of Parkinson's disease. J Am Coll Nutr 18 (1999) 413-423
160. Neff F., Wei X., Nolker C., Bacher M., Du Y., and Dodel R. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev 7 (2008) 501-507
161. Evans J.R., and Barker R.A. Neurotrophic factors as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets 12 (2008) 437-447
162. Factor S.A. Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics 5 (2008) 164-180
163. LeWitt P.A., and Taylor D.C. Protection against Parkinson's disease progression: clinical experience. Neurotherapeutics 5 (2008) 210-225
164. Anden N.E., Carlsson A., Kerstell J., Magnusson T., Olsson R., Roos B.E., et al. Oral l-dopa treatment of parkinsonism. Acta Med Scand 187 (1970) 247-255
165. Fabbrini G., Mouradian M.M., Juncos J.L., Schlegel J., Mohr E., and Chase T.N. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part i. Ann Neurol 24 (1988) 366-371
166. Mouradian M.M., Juncos J.L., Fabbrini G., Schlegel J., Bartko J.J., and Chase T.N. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part ii. Ann Neurol 24 (1988) 372-378
167. Ramaker C., and van Hilten J.J. Bromocriptine versus levodopa in early Parkinson's disease. Cochrane Database Syst Rev (2000) CD002258
168. Asanuma M., and Miyazaki I. Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease. Curr Pharm Des 14 (2008) 1428-1434
169. Simola N., Morelli M., and Pinna A. Adenosine a2a receptor antagonists and Parkinson's disease: state of the art and future directions. Curr Pharm Des 14 (2008) 1475-1489
170. LeWitt P.A., Guttman M., Tetrud J.W., Tuite P.J., Mori A., Chaikin P., et al. Adenosine a2a receptor antagonist istradefylline (kw-6002) reduces "Off" Time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-us-005). Ann Neurol 63 (2008) 295-302
171. Guridi J., Obeso J.A., Rodriguez-Oroz M.C., Lozano A.A., and Manrique M. L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's disease. Neurosurgery 62 (2008) 311-323 discussion 323-315
172. Herzog J., Pogarell O., Pinsker M.O., Kupsch A., Oertel W.H., Lindvall O., et al. Deep brain stimulation in Parkinson's disease following fetal nigral transplantation. Mov Disord 23 (2008) 1293-1296
173. Limousin P., and Martinez-Torres I. Deep brain stimulation for Parkinson's disease. Neurotherapeutics 5 (2008) 309-319
174. Montgomery Jr. E.B., and Gale J.T. Mechanisms of action of deep brain stimulation (dbs). Neurosci Biobehav Rev 32 (2008) 388-407
175. Remple M.S., Sarpong Y., and Neimat J.S. Frontiers in the surgical treatment of Parkinson's disease. Expert Rev Neurother 8 (2008) 897-906
176. Wider C., Pollo C., Bloch J., Burkhard P.R., and Vingerhoets F.J. Long-term outcome of 50 consecutive Parkinson's disease patients treated with subthalamic deep brain stimulation. Parkinson Relat Disord 14 (2008) 114-119
177. Yamada K., Goto S., Hamasaki T., and Kuratsu J.I. Effect of bilateral subthalamic nucleus stimulation on levodopa-unresponsive axial symptoms in Parkinson's disease. Acta Neurochir (Wien) 150 (2008) 15-22 discussion 22
178. Yu H., and Neimat J.S. The treatment of movement disorders by deep brain stimulation. Neurotherapeutics 5 (2008) 26-36
179. Braak H., and Del Tredici K. Assessing fetal nerve cell grafts in Parkinson's disease. Nat Med 14 (2008) 483-485
180. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., and Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14 (2008) 504-506
181. Li J.Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14 (2008) 501-503
182. Mendez I., Vinuela A., Astradsson A., Mukhida K., Hallett P., Robertson H., et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 14 (2008) 507-509
183. Bankiewicz K.S., Plunkett R.J., Jacobowitz D.M., Porrino L., di Porzio U., London W.T., et al. The effect of fetal mesencephalon implants on primate mptp-induced parkinsonism. Histochemical and behavioral studies. J Neurosurg 72 (1990) 231-244
184. Lindner M.D., Winn S.R., Baetge E.E., Hammang J.P., Gentile F.T., Doherty E., et al. Implantation of encapsulated catecholamine and gdnf-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Exp Neurol 132 (1995) 62-76
185. Barkats M., Nakao N., Grasbon-Frodl E.M., Bilang-Bleuel A., Revah F., Mallet J., et al. Intrastriatal grafts of embryonic mesencephalic rat neurons genetically modified using an adenovirus encoding human cu/zn superoxide dismutase. Neuroscience 78 (1997) 703-713
186. Clarke D.J., Brundin P., Strecker R.E., Nilsson O.G., Bjorklund A., and Lindvall O. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: Ultrastructural evidence for synapse formation using tyrosine hydroxylase immunocytochemistry. Exp Brain Res 73 (1988) 115-126
187. Costantini L.C., Jacoby D.R., Wang S., Fraefel C., Breakefield X.O., and Isacson O. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Hum Gene Ther 10 (1999) 2481-2494
188. Lin Q., Cunningham L.A., Epstein L.G., Pechan P.A., Short M.P., Fleet C., et al. Human fetal astrocytes as an ex vivo gene therapy vehicle for delivering biologically active nerve growth factor. Hum Gene Ther 8 (1997) 331-339
189. Redmond D.E., Sladek Jr. J.R., Roth R.H., Collier T.J., Elsworth J.D., Deutch A.Y., et al. Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine. Lancet 1 (1986) 1125-1127
190. Perlow M.J., Freed W.J., Hoffer B.J., Seiger A., Olson L., and Wyatt R.J. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204 (1979) 643-647
191. Moses D., Drago J., Teper Y., Gantois I., Finkelstein D.I., and Horne M.K. Fetal striatum- and ventral mesencephalon-derived expanded neurospheres rescue dopaminergic neurons in vitro and the nigro-striatal system in vivo. Neuroscience 154 (2008) 606-620
192. Mandel R.J., Burger C., and Snyder R.O. Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production. Exp Neurol 209 (2008) 58-71
193. Porras G., and Bezard E. Preclinical development of gene therapy for Parkinson's disease. Exp Neurol 209 (2008) 72-81
194. Kordower J.H., and Olanow C.W. Regulatable promoters and gene therapy for Parkinson's disease: Is the only thing to fear, fear itself?. Exp Neurol 209 (2008) 34-40
195. Ostenfeld T., Tai Y.T., Martin P., Deglon N., Aebischer P., and Svendsen C.N. Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. J Neurosci Res 69 (2002) 955-965
196. Sun J., Gao Y., Yang L., Li Z., Lu G., and Yew D. Neural-tube-derived neuroepithelial stem cells: A new transplant resource for Parkinson's disease. Neuroreport 18 (2007) 543-547
197. Takagi Y., Takahashi J., Saiki H., Morizane A., Hayashi T., Kishi Y., et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 115 (2005) 102-109
198. Lindvall O., Backlund E.O., Farde L., Sedvall G., Freedman R., Hoffer B., et al. Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to the putamen. Ann Neurol 22 (1987) 457-468
199. Madrazo I., Drucker-Colin R., Diaz V., Martinez-Mata J., Torres C., and Becerril J.J. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N Engl J Med 316 (1987) 831-834
200. Kordower J.H. In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease. Ann Neurol 53 Suppl. 3 (2003) S120-132 discussion S132-124
201. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9 (2003) 589-595
202. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59 (2006) 459-466
203. Nutt J.G., Burchiel K.J., Comella C.L., Jankovic J., Lang A.E., Laws E.R., et al. ICV GDNF study group: implanted intracerbroventricular glial cell line-derived neurotrophic factor. Randomized, double-blind trial of glial cell line-derived neurotophic factor (GDNF) in PD. Neurology 60 (2003) 69-73
204. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., and Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102 (2005) 216-222
205. Slevin J.T., Gash D.M., Smith C.D., Gerhardt G.A., Kryscio R., Chebrolu H., et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg 106 (2007) 614-620
206. Horger B.A., Nishimura M.C., Armanini M.P., Wang L.C., Poulsen K.T., Rosenblad C., et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 18 (1998) 4929-4937
207. Grondin R., Zhang Z., Ai Y., Ding F., Walton A.A., Surgener S.P., et al. Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of mptp-lesioned rhesus monkeys. Cell Transplant 17 (2008) 373-381
208. Marks Jr. W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., et al. Safety and tolerability of intraputaminal delivery of cere-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase i trial. Lancet Neurol 7 (2008) 400-408
209. Cleren C., Yang L., Lorenzo B., Calingasan N.Y., Schomer A., Sireci A., et al. Therapeutic effects of coenzyme q10 (coq10) and reduced coq10 in the mptp model of parkinsonism. J Neurochem 104 (2008) 1613-1621
210. Bayes M., Rabasseda X., and Prous J.R. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 29 (2007) 303-311
211. Dass B., Olanow C.W., and Kordower J.H. Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology 66 (2006) S89-S103
212. Maguire-Zeiss K.A., Bowers W.J., and Federoff H.J. Hsv vector-mediated gene delivery to the central nervous system. Curr Opin Mol Ther 3 (2001) 482-490
213. Ross C.A., and Pickart C.M. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol 14 (2004) 703-711
214. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., and Lansbury Jr. P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc Natl Acad Sci USA 97 (2000) 571-576
215. Tashiro M., Kojima M., Kihara H., Kasai K., Kamiyoshihara T., Ueda K., et al. Characterization of fibrillation process of alpha-synuclein at the initial stage. Biochem Biophys Res Commun 369 (2008) 910-914
216. Kheterpal I., Lashuel H.A., Hartley D.M., Walz T., Lansbury Jr. P.T., and Wetzel R. Abeta protofibrils possess a stable core structure resistant to hydrogen exchange. Biochemistry 42 (2003) 14092-14098
217. Stefani M., and Dobson C.M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 81 (2003) 678-699
218. Caughey B., and Lansbury P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26 (2003) 267-298
219. Cookson M.R., and van der Brug M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol 209 (2008) 5-11
220. Hasegawa T., Matsuzaki-Kobayashi M., Takeda A., Sugeno N., Kikuchi A., Furukawa K., et al. Alpha-synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson's disease. FEBS Lett 580 (2006) 2147-2152
221. Meredith S.C. Protein denaturation and aggregation: cellular responses to denatured and aggregated proteins. Ann N Y Acad Sci 1066 (2005) 181-221
222. El-Agnaf O.M., Paleologou K.E., Greer B., Abogrein A.M., King J.E., Salem S.A., et al. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J 18 (2004) 1315-1317
223. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416 (2002) 507-511
224. El-Agnaf O.M., Nagala S., Patel B.P., and Austen B.M. Non-fibrillar oligomeric species of the amyloid abri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils. J Mol Biol 310 (2001) 157-168
225. El-Agnaf O.M., Walsh D.M., and Allsop D. Soluble oligomers for the diagnosis of neurodegenerative diseases. Lancet Neurol 2 (2003) 461-462
226. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., et al. Diffusible, nonfibrillar ligands derived from abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95 (1998) 6448-6453
227. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
228. Tetzlaff J.E., Putcha P., Outeiro T.F., Ivanov A., Berezovska O., Hyman B.T., et al. Chip targets toxic alpha-synuclein oligomers for degradation. J Biol Chem 283 (2008) 17962-17968
229. Kawahara K., Hashimoto M., Bar-On P., Ho G.J., Crews L., Mizuno H., et al. Alpha-synuclein aggregates interfere with parkin solubility and distribution: role in the pathogenesis of Parkinson disease. J Biol Chem 283 (2008) 6979-6987
230. Windisch M., Wolf H., Hutter-Paier B., and Wronski R. The role of alpha-synuclein in neurodegenerative diseases: a potential target for new treatment strategies?. Neurodegener Dis 5 (2008) 218-221
231. Ischiropoulos H. Oxidative modifications of alpha-synuclein. Ann N Y Acad Sci 991 (2003) 93-100
232. Lee H.J., Shin S.Y., Choi C., Lee Y.H., and Lee S.J. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem 277 (2002) 5411-5417
233. Li J., Uversky V.N., and Fink A.L. Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations a30p and a53t. Neurotoxicology 23 (2002) 553-567
234. Tanaka M., Kim Y.M., Lee G., Junn E., Iwatsubo T., and Mouradian M.M. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 279 (2004) 4625-4631
235. Murphy R.M. Peptide aggregation in neurodegenerative disease. Annu Rev Biomed Eng 4 (2002) 155-174
236. Ecroyd H., and Carver J.A. The effect of small molecules in modulating the chaperone activity of alphab-crystallin against ordered and disordered protein aggregation. FEBS J 275 (2008) 935-947
237. Madine J., Doig A.J., and Middleton D.A. Design of an n-methylated peptide inhibitor of alpha-synuclein aggregation guided by solid-state NMR. J Am Chem Soc 130 (2008) 7873-7881
238. Sciarretta K.L., Gordon D.J., and Meredith S.C. Peptide-based inhibitors of amyloid assembly. Methods Enzymol 413 (2006) 273-312
239. Abe K., Kobayashi N., Sode K., and Ikebukuro K. Peptide ligand screening of alpha-synuclein aggregation modulators by in silico panning. BMC Bioinformatics 8 (2007) 451
240. Bar-On P., Crews L., Koob A.O., Mizuno H., Adame A., Spencer B., et al. Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem 105 (2008) 1656-1667
241. Brandt I., Gerard M., Sergeant K., Devreese B., Baekelandt V., Augustyns K., et al. Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein. Peptides 29 (2008) 1472-1478
242. Outeiro T.F., Kontopoulos E., Altmann S.M., Kufareva I., Strathearn K.E., Amore A.M., et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317 (2007) 516-519
243. Morrison B.E., Majdzadeh N., and D'Mello S.R. Histone deacetylases: focus on the nervous system. Cell Mol Life Sci 64 (2007) 2258-2269
244. Ono K., and Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 97 (2006) 105-115
245. Uversky V.N., Li J., Souillac P., Millett I.S., Doniach S., Jakes R., et al. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem 277 (2002) 11970-11978
246. Hashimoto M., Rockenstein E., Mante M., Crews L., Bar-On P., Gage F.H., et al. An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Gene Ther 11 (2004) 1713-1723
247. Messer A., and McLear J. The therapeutic potential of intrabodies in neurologic disorders: focus on Huntington and Parkinson diseases. BioDrugs 20 (2006) 327-333
248. Haidaris C.G., Malone J., Sherrill L.A., Bliss J.M., Gaspari A.A., Insel R.A., et al. Recombinant human antibody single chain variable fragments reactive with candida albicans surface antigens. J Immunol Methods 257 (2001) 185-202
249. Malone J., and Sullivan M.A. Analysis of antibody selection by phage display utilizing anti-phenobarbital antibodies. J Mol Recognit 9 (1996) 738-745
250. Emadi S., Barkhordarian H., Wang M.S., Schulz P., and Sierks M.R. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol 368 (2007) 1132-1144
251. Emadi S., Liu R., Yuan B., Schulz P., McAllister C., Lyubchenko Y., et al. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 43 (2004) 2871-2878
252. Lynch S.M., Zhou C., and Messer A. An scfv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J Mol Biol 377 (2008) 136-147
253. Zhou C., Emadi S., Sierks M.R., and Messer A. A human single-chain fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther 10 (2004) 1023-1031
254. Giasson B.I., Murray I.V., Trojanowski J.Q., and Lee V.M. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 276 (2001) 2380-2386
255. Wuertzer C.A., Sullivan M.A., Qiu X., and Federoff H.J. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther 16 (2008) 481-486
256. Fortin D.L., Nemani V.M., Voglmaier S.M., Anthony M.D., Ryan T.A., and Edwards R.H. Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci 25 (2005) 10913-10921
257. Lee H.J., Patel S., and Lee S.J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 25 (2005) 6016-6024